Market news

Globus Medical (GMED) has drawn investor attention after recent price moves left the stock down about 10% over the past month and roughly 5% lower over the past 3 months. Set against that short term pullback, Globus Medical’s 1 year total shareholder return of 32.5% and 3 year total shareholder return of 50.8% point to a very different picture from the recent 1 month share price decline of about 9.9% and 3 month share price drop of roughly 5.4%. This signals that momentum has cooled recently...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.

Globus Medical, NetApp and Assurant stand out for strong projected sales growth as investors navigate renewed Middle East tensions.

Globus Medical (NYSE:GMED) announced that its Excelsius3D imaging system has received CE marking for use in the European Union and United Kingdom. The approval allows Globus Medical to begin commercial launch of the Excelsius3D system across these markets. Excelsius3D is part of Globus Medical's broader imaging and navigation platform for spine and orthopedic procedures. For readers interested in more ways to get exposure to surgical imaging, guidance and automation trends, explore 36...

The Excelsius3D system is a mobile imaging platform combining 3D CT, 2D fluoroscopy, and digital radiography.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

The mean of analysts' price targets for Globus Medical (GMED) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Globus Medical (GMED) has drawn fresh attention after recent trading left the stock with a last close of US$83.10. Investors are weighing this price against the company’s current fundamentals and valuation profile. Over the past year, Globus Medical has offered a 35.10% total shareholder return, while the share price return over the same period is lower, which suggests that dividends or other distributions have added meaningfully to investor outcomes. At the same time, the 30 day share price...

AUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC...

Globus Medical is rated a buy, targeting a 17.5% return over four quarters with a constant 10.56x EV/EBITDA multiple. Click here to read this GMED stock update.

Stephen T Zarrilli, Director, on August 18, 2026, sold 25,000 shares in Globus Medical (GMED) for $2

Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Globus Medical has seen its assessed fair value cut from US$107.42 to US$103.23, a modest 3.9% trim that reflects a cooler view on upside from current levels. Recent research has highlighted a split narrative, with some analysts pointing to earnings strength and integration progress, while others focus on softer growth expectations and a tighter trading range for price targets. As you read on, you will see how these differing views fit together and how to track the evolving story around...

Globus Medical (GMED) has been in focus after a recent upgrade to Zacks Rank #1, which came shortly after the company reaffirmed its 2026 revenue guidance and released its latest quarterly earnings. See our latest analysis for Globus Medical. Over the past year, Globus Medical has seen a 36.44% total shareholder return and a 10.96% 90 day share price return. This suggests momentum has been building again around the recent earnings update and reaffirmed 2026 guidance. If you are looking for...

Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tipranks Press Release.

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Globus Medical (GMED) reported Q2 adjusted earnings late Thursday of $1.34 per diluted share, up fro

AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026: Worldwide net sales were $789.6 million, an increase of 5.9%, or an increase of 5.6% on a constant currency basis.GAAP net income for the quarter was $151.6 million.GAAP diluted earnings per share (“EPS”) was $1.10, a decrease of 26.2%, primarily driven by the bargain

Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

What To Expect From Globus Medical’s (GMED) Q2 Earnings

Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.

Globus Medical Inc (GMED) has an average rating of overweight and mean price target of $102.77, acco

GMED is gaining share in musculoskeletal solutions with strong implant and trauma growth, backed by a debt-free balance sheet despite cost and FX pressures.

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.

Detailed price information for Enovis Corp (ENOV-N) from The Globe and Mail including charting and trades.

AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30

Sector rally lifts Globus Medical stock Globus Medical (GMED) climbed 5.3% in the latest session, moving alongside a broad advance across medical device stocks as institutional investors appeared to add exposure across multiple medical technology companies. See our latest analysis for Globus Medical. At a share price of $80.50, Globus Medical has recently slipped over the past quarter yet still posts a 1-year total shareholder return of 43.83%, suggesting longer term holders have seen...